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Editorial Comment
Further Evidence in Support of
Anticoagulant Therapy Before
Elective Cardioversion of
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JOHN P. DIMARCO . MD, PHD, FACC
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Atria) fibrillation is by far the most common sustained
cardiac arrhythmia . ics prevalence increases with advancing
age and >4% of the United States population over age 80
years are affected (I) . The presence of atria[ fibrillation is
associated with a higher total mortality rate and a dramati-
cally increased risk for stroke and other embolic events .
Although atrial fibrillation has been recognized as a major
clinical problem for hundreds of years, many aspects of its
management remain controversial . In recent years many of
the traditional approaches to the patient with atrial fibrilla-
tion have been challenged . The role of digoxin has been
questioned, with recent studies suggesting that this former
mainstay of therapy should now play only a subsidiary role
(2). Quinidine has been shown to be helpful for maintaining
sinus rhythm in some patients, but only at the cost off, slight
increase in long-term mortality (3) . Long-term anticoagulant
therapy, formerly reserved chiefly for those with a prosthetic
valve, rheumatic heart disease or prior stroke, is now
recommended for the majority of patients with chronic atrial
fibrillation (1).
The present study . In this issue of the Journal . Arnold et
al
. (4) provide information that at least one traditional
recommendation, the need for anticoagulation before elec-
trical cardioversion, remains valid and is perhaps deserving
of further emphasis . In their report Arnold et al . (4) retro-
spectively review the outcome of 454 elective direct current
cardioversions of either atrial fibrillation or atrial flutter
.
Approximately two thirds of the episodes occurred after
cardiac surgery . Episodes were of at least 48-h duration
.
Patients with and without an embolic event were analyzed
on the basis of anticoagulation status . Anticoagulant therapy
was not randomly assigned hot was selected by the individ-
ual patient's physician . Embolic events were seen only in
patients with atrial fibrillation who were not receiving anli-
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coagulant therapy : 2 of 117 postoperative patients and 4 of 64
nonsurgical patients . Significantly, five of the six patients
with embolism had atrial fibrillation of <I week's duration .
No patient with atrial flutter developed an embolic event
with or without anticoagulant therapy .
Clinical Implications . What are the practical clinical im-
plications of these observations? The data are consistent
with previous uncontrolled retrospective studies (5). The
short duration of atria] fibrillation in five of the six patients
with embolism and the occurrence of embolism in postoper-
ative atrial fibrillation are important factors for clinicians .
The total lack of embolism in patients receiving anticuagu-
lant agents is impressive .
The data presented by Arnold ct al, (4) support the usual
clinical practice of a period of anticoagulant therapy before
an elective cardioversion of atrial fibrillation . However,
many questions remain . What measure of anticoagulation
provides necessary protection against enlbolization? Other
trials have shown that stroke risk will be reduced and
bleeding minimized even if the international normalized ratio
for the prothromhin time is kept quite low, that is, 1 .5 to 2 5 .
Will this be adequate for cardioversion^ Will short-term
heparin therapy be adequate? What duration of therapy
before and after the attempted cardioversion will be re-
quired'? Is there a role for aspirin if patients at low risk can
be identified? Is card aversion
of atrial flutter without anti-
coagulant therapy really safe? Others (6) have reported
embolism after conversion of atrial flutter and the number of
patients described here is too small to exclude low frequency
events .
Recommendations. 'the report by Arnold et al . (4) has
many of the limitations inherent in a retrospective analysis of
clinical data . However, even a low rate of occurrence of a
devastating complication such as embolic stroke deserves
vigorous efforts at prevention . Recently the American Col-
lege of Chest Physicians (7) made the following recommen-
dations: I) administration of warfarin anticoagulation for 3
weeks before elective cardioversion of atrial fibrillation of
?3 days' duration, 2) continuation of warfarin therapy for 2
to 4 weeks after conversion, 3) administration of heparin
followed by warfarin if cardioversion cannot be postponed
for 3 weeks, and 4) no anticoagulant therapy for atria]
fibrillation of <2 days' duration or for atrial flutter . The data
presented in this report support this conservative approach
.
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